07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals sales and marketing update

Valeant launched an oral formulation of Relistor methylnaltrexone in the U.S. to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The wholesale acquisition cost (WAC) for a 150 mg tablet is $16.67....
07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

Methylnaltrexone regulatory update

FDA approved an NDA from Valeant for oral Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Valeant expects to launch the drug this quarter. The approval triggered a $50...
07:00 , Jul 20, 2016 |  BC Extra  |  Company News

FDA's oral Relistor approval triggers Progenics milestone

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) gained $1.20 (24%) to $6.14 on Wednesday after it and partner Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said FDA approved oral Relistor methylnaltrexone ( MOA-728 ) to treat opioid-induced constipation (OIC)...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

Oral Relistor methylnaltrexone regulatory update

Valeant said FDA extended the PDUFA date by 3 months to July 19 from April 19 for an NDA for oral Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain....
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

2Q milestones

2Q milestones Company Product Indication Event Milestone Ablynx N.V. (Euronext:ABLX) ALX-0171 Respiratory syncytial virus (RSV) infection Ph I/IIa data 2Q16 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Nuplazid pimavanserin Parkinson's disease psychosis (PDP) PDUFA date 5/1/16 Acucela Inc....
08:00 , Jan 25, 2016 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Swedish Orphan Biovitrum deal

Valeant’s PharmaSwiss S.A. division granted Swedish Orphan Biovitrum exclusive rights to commercialize Relistor methylnaltrexone for opioid-induced constipation (OIC) in Western Europe, Czech Republic, Slovakia, Hungary and Russia. Swedish Orphan will be responsible for commercialization, including...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
07:00 , Sep 14, 2015 |  BC Week In Review  |  Clinical News

Oral Relistor methylnaltrexone regulatory update

FDA accepted for review an NDA from Valeant for oral Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The PDUFA date is April 19, 2016. A subcutaneous formulation of...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Oral Relistor methylnaltrexone regulatory update

Valeant submitted an NDA to FDA for oral Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. A subcutaneous formulation of the peripheral mu opioid receptor (MOR; OPRM1 ) antagonist...